Description
Introduction
Diagnostic and prognostic biomarkers will help to identify patients with early Alzheimer's disease, while pharmacogenetic biomarkers can inform prescribing decisions and form the basis of personalized medicine. Biomarkers are at the heart of the development of two high-risk pipeline drugs, bapineuzumab and solanezumab, with combined peak-year sales forecasts of $6.6bn in the seven major markets.
Features and benefits
- Identify the imaging, fluid, and genetic biomarkers currently under clinical evaluation.
- Understand the potential roles of biomarker tests in the diagnosis and treatment of Alzheimer's disease.
- Review the tools used to diagnose Alzheimer's disease by neurologists surveyed by Datamonitor in 2011.
- Quantify the impact that biomarkers may have on the Alzheimer's disease drug market from 2011 to 2020.
- View insights from Datamonitor's interviews with internationally renowned key opinion leaders.
Highlights
- The Alzheimer's disease market is forecast to grow to 2020 at a CAGR of 10.7% from 2011. Catalysts for growth include an aging population, earlier diagnosis, and the introduction of immunotherapies. The absolute impact of biomarkers is predicted to be $6.6bn annually by 2020 with the potential for far greater implications beyond this period.
- The last 2 years have seen a spate of collaborations between drug and diagnostic companies. This has allowed drug developers to be at the forefront of diagnostic research; enabling optimized patient recruitment and generating important biomarker data. Furthermore, the potential for allying a new drug to a companion diagnostic is created.
- Diagnostic biomarkers to identify MCI due to Alzheimer's may increase the likelihood that a drug with an anti-amyloid mechanism will show efficacy. Furthermore, pharmacogenetic biomarkers, such as ApoE4 status with bapineuzumab, can identify patients that will be more likely to respond to a treatment with an acceptable safety profile.
Your key questions answered
- How will biomarker tests alter the diagnostic and therapeutic landscape for Alzheimer's disease?
- Why is early diagnosis so important in Alzheimer's disease and how will biomarker tests facilitate this?
- What will the absolute impact of biomarkers be on the Alzheimer's disease drug market to 2020?
- How will key stakeholders stand to benefit from the advent of personalized medicine?
TOC
Executive Summary
- Strategic scoping and focus
- Datamonitor key findings
- Related reports
OVERVIEW
INTRODUCTION
- Alzheimer's disease diagnosis
- NINCDS-ADRDA criteria
- NIA-AA criteria
ALZHEIMER'S DISEASE BIOMARKERS
- Biomarkers under investigation
- Structural imaging: MRI
- Functional imaging: PET and SPECT
- Fluid biomarker analysis
- Genetic biomarkers
- Potential roles of Alzheimer's disease biomarkers
- Diagnostic and prognostic
- Treatment response
IMPACT OF BIOMARKERS ON THE ALZHEIMER'S DISEASE DRUG MARKET
- Market dynamics
- Biomarkers provide the potential platform for double-digit growth in the Alzheimer's disease market
- Bapineuzumab and solanezumab, two of the potential high-value Alzheimer's immunotherapies, rely heavily on biomarkers
- Indication dynamics
- High value lies in the early treatment of Alzheimer's disease
DIAGNOSTIC STAKEHOLDERS
- Diagnostic companies
- Spate of collaborations between diagnostic companies and drug developers
- There are multiple advantages to a personalized medicine approach to Alzheimer's disease
- Imaging manufacturers
- PET scans will become increasingly common in Alzheimer's disease diagnosis
BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
APPENDIX A
- Physician research methodology
- Physician sample breakdown
- The survey questionnaire
- Diagnosis techniques currently in use for Alzheimer's disease
APPENDIX B
- PharmaVitae Explorer database
- Contributing experts
- Conferences attended
- Forecast methodology
- Market definition for this disease
- Forecast methodology and assumptions
- Report methodology
